Literature DB >> 6769735

Effect of coadministration of thymine or thymidine on the antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil.

S Fujii, S Kitano, K Ikenaka, M Fukushima, H Nakamura, Y Maehara, T Shirasaka.   

Abstract

The antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) on sarcoma was enhanced by oral coadministration of uracil, thymine, or thymidine. The activity was enhanced equally by thymine and by uracil than by thymidine, but thymine caused loss in body weight. The antitumor activity of 5-fluorouracil (5-FU) was also enhanced by thymine or uracil, but both caused loss in body weight. Degradation of 5-FU in vitro was inhibited more by thymine than by uracil. Phosphorylation of 5-FU, however, was not inhibited by uracil, thymine, or thymidine, even at 100 times the concentration of 5-FU. These results suggest that the mechanism of enhancement of the antitumor activity of FT-207 by thymine or thymidine was similar to that by uracil, and that uracil had more effect than thymine or thymidine in enhancing antitumor effect of these drugs to FT-207 without toxicity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6769735

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  7 in total

1.  Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine.

Authors:  M Iigo; A Hoshi; H Kitagawa
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

2.  Elevation of plasma levels of fluorinated pyrimidines by guanosine 5'-monophosphate.

Authors:  M Iigo; Z Yamaizumi; S Nishimura; A Hoshi
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Tissue distribution of [18F]-5-fluorouracil in mice: effects of route of administration, strain, tumour and dose.

Authors:  G W Visser; G C Gorree; G J Peters; J D Herscheid
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Effect of guanosine on antitumor activity of fluorinated pyrimidines against P 388 leukemia.

Authors:  M Iigo; A Hoshi
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study.

Authors:  Wenhua Li; Xiaoying Zhao; Huijie Wang; Xin Liu; Xinmin Zhao; Mingzhu Huang; Lixin Qiu; Wen Zhang; Zhiyu Chen; Weijian Guo; Jin Li; Xiaodong Zhu
Journal:  Oncotarget       Date:  2017-06-06

Review 6.  Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer.

Authors:  Koji Harada; Tarannum Ferdous; Yoshiya Ueyama
Journal:  Jpn Dent Sci Rev       Date:  2016-12-19

7.  Antitumor activity of BOF-A2, a new 5-fluorouracil derivative.

Authors:  S Fujii; M Fukushima; Y Shimamoto; H Ohshimo; T Imaoka; T Shirasaka
Journal:  Jpn J Cancer Res       Date:  1989-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.